According to the WHO, depression affects an estimated 350 million people worldwide, making it one of the most prevalent psychiatric conditions. However, only about half of those who try antidepressant drugs respond to them, and those who do may have to wait several weeks or even months before experiencing relief — a critical failing for people at immediate risk of suicide. Fast-acting antidepressants are thus urgently needed.
Ketamine — a drug primarily used as an anesthetic in veterinary medicine and as a short-term anesthetic and analgesic in hospitals during surgery or other painful procedures — is currently the rising star of depression research.
It appears to ease depression’s most severe symptoms within minutes or hours, even in patients who have a dismal track record with other treatments.
In the first controlled study, researchers reported a 50 percent decline in symptoms of depression within two hours of a ketamine infusion, and one-third of patients were virtually symptom-free within a day. Moreover, patients reported diminished thoughts of suicide a mere 40 minutes after receiving an intravenous infusion of the drug. In some patients, the effects of a single dose can last more than a week.
Clinicians are not alone in studying ketamine’s potential.
Neuroscientists have hailed it as the first breakthrough in depression-drug research in 50 years. Unlike conventional antidepressants — which are used to elevate concentrations of the neurotransmitters serotonin, dopamine or noradrenaline — ketamine influences the glutamate system. Glutamate, the major excitatory neurotransmitter, plays a central role in mediating nearly all forms of brain function, including learning, memory, cognition and emotion.
By blocking glutamate from binding to the NMDA receptor, ketamine leads to an augmented glutamate release, which activates other types of glutamate receptors and enhances the function and density of synapses (the junctions between neurons) in areas of the brain where stress or depression has caused cells to atrophy. Increased synaptic plasticity — the ability of synapses to adjust their strength, which is essential to healthy brain function — could be the neurobiological reason for the apparent therapeutic effect in patients.
However, though ketamine’s promise has stirred excitement among clinicians and neuroscientists, it has also sparked controversy, owing to the drug’s potentially harmful side effects. Depending on the dose, a patient may experience altered physical, spatial and temporal states; larger quantities may induce hallucinations and dissolution of the self.
Intriguingly, ketamine’s psychoactive properties may be responsible for its mood-enhancing effect. Psychedelic and psycholytic treatments — popular in the 1960s and 1970s, before research was severely restricted and interest in the clinical use of psychedelics faded — were based on the notion that the drug-induced psychological experience was essential to facilitating the psychotherapeutic process.
According to this view, the altered state of consciousness produced by ketamine — particularly the dissolution of the self’s boundaries and the experience of union with the world — might constitute a profound and meaningful experience for a patient. Integrating this experience into the psychotherapeutic process might facilitate subsequent behavioral changes. In other words, drugs like ketamine that quickly increase neuroplasticity might be particularly clinically efficient in combination with psychotherapeutic interventions.
Unfortunately, research on ketamine addicts and those who take it in large doses as a party drug has revealed that its use may lead to learning and perception problems, as well as memory disorders. Another concern is that ketamine’s benefits may be relatively fleeting. As a result, ketamine may never develop into an accepted treatment for depression in its current form.
In fact, ketamine’s future as a therapy for depression would be uncertain even if its efficacy were more strongly established. Because ketamine has been available for decades, there is no patent for it, so pharmaceutical companies have little financial incentive to carry out research on the drug and seek approval for its use as an antidepressant.
Nonetheless, research on ketamine’s chemistry might help to identify mechanisms for addressing treatment-resistant depression that are based on glutamate-driven neuroplasticity. Indeed, pharmaceutical companies have already begun to investigate other NMDA-receptor antagonists, together with drugs that act on a different part of the glutamate system, as possible treatments for depression. This research could eventually lead to an entirely new class of antidepressant — and relief for millions of people worldwide.
Simone Grimm is a researcher in the department of psychiatry, psychotherapy and psychosomatics at the University of Zurich.
Copyright: Project Syndicate
The Chinese Communist Party (CCP) has long been expansionist and contemptuous of international law. Under Chinese President Xi Jinping (習近平), the CCP regime has become more despotic, coercive and punitive. As part of its strategy to annex Taiwan, Beijing has sought to erase the island democracy’s international identity by bribing countries to sever diplomatic ties with Taipei. One by one, China has peeled away Taiwan’s remaining diplomatic partners, leaving just 12 countries (mostly small developing states) and the Vatican recognizing Taiwan as a sovereign nation. Taiwan’s formal international space has shrunk dramatically. Yet even as Beijing has scored diplomatic successes, its overreach
In her article in Foreign Affairs, “A Perfect Storm for Taiwan in 2026?,” Yun Sun (孫韻), director of the China program at the Stimson Center in Washington, said that the US has grown indifferent to Taiwan, contending that, since it has long been the fear of US intervention — and the Chinese People’s Liberation Army’s (PLA) inability to prevail against US forces — that has deterred China from using force against Taiwan, this perceived indifference from the US could lead China to conclude that a window of opportunity for a Taiwan invasion has opened this year. Most notably, she observes that
For Taiwan, the ongoing US and Israeli strikes on Iranian targets are a warning signal: When a major power stretches the boundaries of self-defense, smaller states feel the tremors first. Taiwan’s security rests on two pillars: US deterrence and the credibility of international law. The first deters coercion from China. The second legitimizes Taiwan’s place in the international community. One is material. The other is moral. Both are indispensable. Under the UN Charter, force is lawful only in response to an armed attack or with UN Security Council authorization. Even pre-emptive self-defense — long debated — requires a demonstrably imminent
Since being re-elected, US President Donald Trump has consistently taken concrete action to counter China and to safeguard the interests of the US and other democratic nations. The attacks on Iran, the earlier capture of deposed of Venezuelan president Nicolas Maduro and efforts to remove Chinese influence from the Panama Canal all demonstrate that, as tensions with Beijing intensify, Washington has adopted a hardline stance aimed at weakening its power. Iran and Venezuela are important allies and major oil suppliers of China, and the US has effectively decapitated both. The US has continuously strengthened its military presence in the Philippines. Japanese Prime
RSS